Novo Holdings A/S
Q3 2026 13F-HR Holdings
Net value change ($000)
-232,529
(-13.5%)
New positions
3
Sold out positions
1
Turnover %
8.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| OBSIDIAN THERAPEUTICS INC | 42,892 | NEW |
| CRM | 28,667 | 46.5% |
| SRRK | 22,227 | NEW |
| INSM | 19,593 | 152.2% |
| BN | 13,261 | 8.9% |
| CTNM | 9,448 | NEW |
| BABA | 2,975 | 12.0% |
| DYN | 840 | 3.9% |
Top Reduces (Value $000, Stocks/ETFs)
| MPLT | -110,866 | -83.9% |
| CRNX | -49,394 | -100.0% |
| MIRM | -35,539 | -27.0% |
| AVALYN PHARMACEUTICALS INC | -29,571 | -23.1% |
| HEMAB THERAPEUTICS HLDGS INC | -24,624 | -16.0% |
| ALMS | -21,716 | -70.2% |
| ASML | -16,878 | -8.9% |
| AVBP | -16,531 | -31.7% |
| PHVS | -16,076 | -33.2% |
| FND | -10,799 | -22.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|